- Home
- EPC vs EWTX Comparison
EPC vs EWTX Comparison
Compare EPC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- EWTX
- Stock Information
- Founded
- EPC 1999
- EWTX 2017
- Country
- EPC United States
- EWTX United States
- Employees
- EPC N/A
- EWTX N/A
- Industry
- EPC Package Goods/Cosmetics
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- EWTX Health Care
- Exchange
- EPC Nasdaq
- EWTX Nasdaq
- Market Cap
- EPC 1.4B
- EWTX 1.2B
- IPO Year
- EPC 2000
- EWTX 2021
- Fundamental
- Price
- EPC $24.44
- EWTX $13.00
- Analyst Decision
- EPC Buy
- EWTX Buy
- Analyst Count
- EPC 7
- EWTX 9
- Target Price
- EPC $33.00
- EWTX $39.89
- AVG Volume (30 Days)
- EPC 756.0K
- EWTX 971.8K
- Earning Date
- EPC 08-05-2025
- EWTX 08-07-2025
- Dividend Yield
- EPC 2.56%
- EWTX N/A
- EPS Growth
- EPC N/A
- EWTX N/A
- EPS
- EPC 1.72
- EWTX N/A
- Revenue
- EPC $2,224,500,000.00
- EWTX N/A
- Revenue This Year
- EPC $0.90
- EWTX N/A
- Revenue Next Year
- EPC $2.33
- EWTX N/A
- P/E Ratio
- EPC $13.60
- EWTX N/A
- Revenue Growth
- EPC N/A
- EWTX N/A
- 52 Week Low
- EPC $22.61
- EWTX $10.60
- 52 Week High
- EPC $41.50
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- EPC 37.52
- EWTX 33.37
- Support Level
- EPC $23.05
- EWTX $12.15
- Resistance Level
- EPC $24.43
- EWTX $13.84
- Average True Range (ATR)
- EPC 0.76
- EWTX 0.69
- MACD
- EPC 0.08
- EWTX -0.19
- Stochastic Oscillator
- EPC 28.53
- EWTX 19.28
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.